Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder caused by mutations in the DMD gene, which leads to the absence or near absence of dystrophin, a critical protein for muscle strength and stability. However, for certain individuals, promising treatments such as exon skipping therapies offer hope—especially exon 51 skipping, which is the most commonly targeted exon in current therapies. In this article, we explore which mutations and deletions are amenable to exon 51 skipping and how to determine if a patient may benefit from this therapy.
Table of Contents
What Is Exon 51 Skipping Therapy?
Exon 51 skipping is a precision medicine approach that uses synthetic molecules (called antisense oligonucleotides) to “skip” exon 51 during the processing of the DMD gene’s messenger RNA (mRNA). By skipping exon 51, the treatment can restore the reading frame of the gene, allowing the body to produce a shorter but functional version of dystrophin.
Approved Exon 51 Skipping Therapy
Eteplirsen (Exondys 51) – Approved by the U.S. FDA for treating DMD patients with mutations amenable to exon 51 skipping.
Why Is Exon 51 Important in DMD?
About 13% of patients with DMD have mutations that are amenable to exon 51 skipping, making it the most common exon skipping target in current therapies. This makes it highly relevant for many families seeking cutting-edge treatments for Duchenne.
Deletions Amenable for Exon 51 Skipping
Exon 51 skipping represents a targeted therapeutic strategy for a subset of Duchenne Muscular Dystrophy patients, specifically those with deletions involving exons: 3-50, 4-50, 5-50, 6-50, 9-50, 10-50, 11-50, 13-50, 14-50, 15-50, 16-50, 17-50, 19-50, 21-50, 23-50, 24-50, 25-50, 26-50, 27-50, 28-50, 29-50, 30-50, 31-50, 32-50, 33-50, 34-50, 35-50, 36-50, 37-50, 38-50, 39-50, 40-50, 41-50, 42-50, 43-50, 45-50, 47-50, 48-50, 49-50, 50, 52, 52-61, 52-63, 52-64, 52-66, 52-76.
Discover Our Exon Deletion Search Tool
To be a candidate for exon 51 skipping, a patient must have a frameshifting deletion that can be corrected by skipping exon 51. The goal is to bring the DMD gene back into the correct reading frame.
Common Deletions Amenable to Exon 51 Skipping
If genetic testing shows one of the following deletions, exon 51 skipping therapy may be applicable:
- Deletion of exon 50
- Deletion of exons 48–50
- Deletion of exons 47–50
- Deletion of exons 49–50
- Deletion of exon 52
- Deletion of exons 52–63
- Deletion of exons 45–50 (in some cases depending on frame status)
These deletions disrupt the reading frame in a way that can be restored by skipping exon 51, potentially producing a functional dystrophin protein.
Mutations Amenable to Exon 51 Skipping
Mutations amenable to exon 51 skipping in Duchenne muscular dystrophy include the following exons: 3-50, 4-50, 5-50, 6-50, 9-50, 10-50, 11-50, 13-50, 14-50, 15-50, 16-50, 17-50, 19-50, 21-50, 23-50, 24-50, 25-50, 26-50, 27-50, 28-50, 29-50, 30-50, 31-50, 32-50, 33-50, 34-50, 35-50, 36-50, 37-50, 38-50, 39-50, 40-50, 41-50, 42-50, 43-50, 45-50, 47-50, 48-50, 49-50, 50, 52, 52-61, 52-63, 52-64, 52-66, 52-76.
Exon 51 Skipping Therapy: What to Expect
If your child qualifies, eteplirsen may be an option. This therapy is administered through weekly intravenous infusions and is designed to slow the progression of muscle degeneration.
Benefits:
- Slower disease progression
- Improved dystrophin production
- Potential preservation of ambulation and lung function
Limitations:
- This is not a cure, but a disease-modifying treatment.
- Works only for specific mutations amenable to exon 51 skipping.
- Requires long-term commitment and regular follow-up.
Summary: Is Your Child a Candidate for Exon 51 Skipping?
If your child has been diagnosed with DMD and has a mutation near exon 51, such as a deletion of exon 50 or exon 52, there is a possibility they could benefit from exon 51 skipping therapy.
🔍 Key Takeaways:
- Exon 51 skipping helps restore the dystrophin reading frame in specific deletions.
- About 13% of DMD patients are eligible.
- Genetic testing is essential to determine eligibility.
- Therapies like eteplirsen are FDA-approved for exon 51-amenable mutations.
Learn More: Upcoming Exon 51 Skipping Therapies for the Treatment of Duchenne Muscular Dystrophy
